Company: CSCIF
Filing Date: 2025-04-09
Form Type: 20-F
Source: 0001641172-25-003456
Chunk: 83

Company: COSCIENS Biopharma Inc.
Filing Date: 2025-04-09
Form: 20-F
Item: Item 5
Chunk 83
---
 approval requirements;                                                                       
  the number and characteristics of product candidates                                                                                  
  the outcome, timing, and cost of regulatory approvals;                                                                                
  delays that may be caused by changing regulatory requirements;                                                                        
  the cost and timing of hiring new employees to support                                                                                
  the costs involved                                                                                                                    
  the costs of filing and prosecuting intellectual property                                                                             
  the costs associated with any potential late receipt                                                                                  
  the potential costs associated with foreign currency                                                                                  
  our ability to expand our customer base and related                                                                                   
  the                                                                                                                                   
  the                                                                                                                                   
  the                                                                                                                                   
  the                                                                                                                                   
  the                                                                                                                                   

Contractual
obligations and commitments as of December 31, 2024

Significant
expenditure contracted for at the end of the reporting period but not recognized as liabilities is as follows:

  (in thousands of US dollars)      TOTAL             
                                    $                 
  Less than 1 year                             1,287  
  1 - 5 years                                     34  
                                               1,321  

The
Company previously entered into license agreements with Agriculture Canada (AG) for a technology to increase the concentration of avenanthramides
in selected oat and with University of Alberta for a Pressurized Gaz expanded Technology (PGX) for the processing of various polymers.
The royalty percentage rate would be 2% strictly for sales made from avenanthramides produced from the AG technology while royalty percentage
rates would range between 1.0% to 3.5% for sales made from products manufactured using the PGX Technology, the rate being according to
the classification of the resulting product (cosmeceutical, nutraceutical, pharmaceutical).

Contingencies

From
time to time, the Company may be a party to litigation and subject to claims incidental to its business. Although the results of litigation
and claims cannot be predicted with certainty, the Company currently believes that the final outcome of these matters will not have a
material adverse effect on its business. At each reporting period, the Company evaluates whether or not a potential loss amount or a
potential range of loss is probable and reasonably estimable, requiring recognition of a loss accrual, or whether the potential loss
is reasonably possible, requiring potential disclosure.

Critical
Accounting Estimates and Judgments

Critical
accounting estimates and judgements are described in Note 3 to our audited consolidated financial statements as of December 31, 2024,
and 2023 and